Current murine models and new developments in H3K27M diffuse midline gliomas

John P. Welby, Tatiana Kaptzan, Anton Wohl, Timothy E. Peterson, Aditya Raghunathan, Desmond A. Brown, Shiv K. Gupta, Liang Zhang, David Daniels

Research output: Contribution to journalArticle

Abstract

Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse Intrinsic Pontine Glioma (DIPG), which is the most aggressive form of pediatric glioma with a dire prognosis. DIPG are lethal tumors found in younger children with a median survival <1 year from diagnosis. Discovery of the characteristic H3K27M mutations offers opportunity and hope for development of targeted therapies for this deadly disease. The H3K27M mutation, likely through epigenetic alterations in specific H3 lysine trimethylation levels and subsequent gene expression, plays a significant role in pathogenesis of DIPG. Animal models accurately depicting molecular characteristics of H3K27M DIPG are important to elucidate underlying pathologic events and for preclinical drug evaluation. Here we review the past and present DIPG models and describe our efforts developing patient derived cell lines and xenografts from pretreated surgical specimens. Pre-treated surgical samples retain the characteristic genomic and phenotypic hallmarks of DIPG and establish orthotopic tumors in the mouse brainstem that recapitulate radiographic and morphological features of the original human DIPG tumor. These models that contain the H3K27M mutation constitute a valuable tool to further study this devastating disease and ultimately may uncover novel therapeutic vulnerabilities.

Original languageEnglish (US)
Article number92
JournalFrontiers in Oncology
Volume9
Issue numberFEB
DOIs
StatePublished - Jan 1 2019

Fingerprint

Glioma
Mutation
Lysine
Brain Stem Neoplasms
Preclinical Drug Evaluations
Heterografts
Epigenomics
Methionine
Histones
Brain Stem
Neoplasms
Animal Models
Pediatrics
Gene Expression
Cell Line
Survival
Therapeutics

Keywords

  • Diffuse intrinsic pontine glioma
  • DiPG
  • Glioma
  • H3K27M
  • Xenograft

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Current murine models and new developments in H3K27M diffuse midline gliomas. / Welby, John P.; Kaptzan, Tatiana; Wohl, Anton; Peterson, Timothy E.; Raghunathan, Aditya; Brown, Desmond A.; Gupta, Shiv K.; Zhang, Liang; Daniels, David.

In: Frontiers in Oncology, Vol. 9, No. FEB, 92, 01.01.2019.

Research output: Contribution to journalArticle

Welby, JP, Kaptzan, T, Wohl, A, Peterson, TE, Raghunathan, A, Brown, DA, Gupta, SK, Zhang, L & Daniels, D 2019, 'Current murine models and new developments in H3K27M diffuse midline gliomas', Frontiers in Oncology, vol. 9, no. FEB, 92. https://doi.org/10.3389/fonc.2019.00092
Welby, John P. ; Kaptzan, Tatiana ; Wohl, Anton ; Peterson, Timothy E. ; Raghunathan, Aditya ; Brown, Desmond A. ; Gupta, Shiv K. ; Zhang, Liang ; Daniels, David. / Current murine models and new developments in H3K27M diffuse midline gliomas. In: Frontiers in Oncology. 2019 ; Vol. 9, No. FEB.
@article{5d75792a9e2248388f23fc2ba62e1437,
title = "Current murine models and new developments in H3K27M diffuse midline gliomas",
abstract = "Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse Intrinsic Pontine Glioma (DIPG), which is the most aggressive form of pediatric glioma with a dire prognosis. DIPG are lethal tumors found in younger children with a median survival <1 year from diagnosis. Discovery of the characteristic H3K27M mutations offers opportunity and hope for development of targeted therapies for this deadly disease. The H3K27M mutation, likely through epigenetic alterations in specific H3 lysine trimethylation levels and subsequent gene expression, plays a significant role in pathogenesis of DIPG. Animal models accurately depicting molecular characteristics of H3K27M DIPG are important to elucidate underlying pathologic events and for preclinical drug evaluation. Here we review the past and present DIPG models and describe our efforts developing patient derived cell lines and xenografts from pretreated surgical specimens. Pre-treated surgical samples retain the characteristic genomic and phenotypic hallmarks of DIPG and establish orthotopic tumors in the mouse brainstem that recapitulate radiographic and morphological features of the original human DIPG tumor. These models that contain the H3K27M mutation constitute a valuable tool to further study this devastating disease and ultimately may uncover novel therapeutic vulnerabilities.",
keywords = "Diffuse intrinsic pontine glioma, DiPG, Glioma, H3K27M, Xenograft",
author = "Welby, {John P.} and Tatiana Kaptzan and Anton Wohl and Peterson, {Timothy E.} and Aditya Raghunathan and Brown, {Desmond A.} and Gupta, {Shiv K.} and Liang Zhang and David Daniels",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fonc.2019.00092",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Current murine models and new developments in H3K27M diffuse midline gliomas

AU - Welby, John P.

AU - Kaptzan, Tatiana

AU - Wohl, Anton

AU - Peterson, Timothy E.

AU - Raghunathan, Aditya

AU - Brown, Desmond A.

AU - Gupta, Shiv K.

AU - Zhang, Liang

AU - Daniels, David

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse Intrinsic Pontine Glioma (DIPG), which is the most aggressive form of pediatric glioma with a dire prognosis. DIPG are lethal tumors found in younger children with a median survival <1 year from diagnosis. Discovery of the characteristic H3K27M mutations offers opportunity and hope for development of targeted therapies for this deadly disease. The H3K27M mutation, likely through epigenetic alterations in specific H3 lysine trimethylation levels and subsequent gene expression, plays a significant role in pathogenesis of DIPG. Animal models accurately depicting molecular characteristics of H3K27M DIPG are important to elucidate underlying pathologic events and for preclinical drug evaluation. Here we review the past and present DIPG models and describe our efforts developing patient derived cell lines and xenografts from pretreated surgical specimens. Pre-treated surgical samples retain the characteristic genomic and phenotypic hallmarks of DIPG and establish orthotopic tumors in the mouse brainstem that recapitulate radiographic and morphological features of the original human DIPG tumor. These models that contain the H3K27M mutation constitute a valuable tool to further study this devastating disease and ultimately may uncover novel therapeutic vulnerabilities.

AB - Diffuse Midline Gliomas with Histone 3-Lysine-27-Methionine (H3K27M) mutation constitute the majority of Diffuse Intrinsic Pontine Glioma (DIPG), which is the most aggressive form of pediatric glioma with a dire prognosis. DIPG are lethal tumors found in younger children with a median survival <1 year from diagnosis. Discovery of the characteristic H3K27M mutations offers opportunity and hope for development of targeted therapies for this deadly disease. The H3K27M mutation, likely through epigenetic alterations in specific H3 lysine trimethylation levels and subsequent gene expression, plays a significant role in pathogenesis of DIPG. Animal models accurately depicting molecular characteristics of H3K27M DIPG are important to elucidate underlying pathologic events and for preclinical drug evaluation. Here we review the past and present DIPG models and describe our efforts developing patient derived cell lines and xenografts from pretreated surgical specimens. Pre-treated surgical samples retain the characteristic genomic and phenotypic hallmarks of DIPG and establish orthotopic tumors in the mouse brainstem that recapitulate radiographic and morphological features of the original human DIPG tumor. These models that contain the H3K27M mutation constitute a valuable tool to further study this devastating disease and ultimately may uncover novel therapeutic vulnerabilities.

KW - Diffuse intrinsic pontine glioma

KW - DiPG

KW - Glioma

KW - H3K27M

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=85063261942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063261942&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00092

DO - 10.3389/fonc.2019.00092

M3 - Article

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - FEB

M1 - 92

ER -